Cutaneous sıde‐effects of the potential COVID‐19 drugs

Kaur

et al. 2021

Advances in Wound Care

133

189

Objective: Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is currently a pandemic. Although pulmonary health has been the primary focus of studies during the early days of COVID-19, development of a comprehensive understanding of this emergent disease requires knowledge of all possible disease manifestations in affected patients. This Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA)-compliant review focuses on cutaneous manifestations reported in COVID-19 patients. Approach: Literature review was conducted using the PubMed database to examine various cutaneous manifestations related to the SARS-CoV-2 infection. Published articles (n = 56) related to search criteria from the onset of the COVID-19 pandemic to June 30, 2020, were included. The primary literature articles included in this study were mainly from France, Spain, Italy, and the United Kingdom. Results: Unique to many other symptoms of COVID-19, its cutaneous manifestations have been found in people of all age groups, including children. The cutaneous manifestations of COVID-19 are varied and include maculopapular, chilblain-like, urticarial, vesicular, livedoid, and petechial lesions. In addition, rashes are common in multisystem inflammatory syndrome in children, a new and serious health condition that shares symptoms with Kawasaki disease and is likely related to COVID-19. In addition, personal protective equipmentrelated skin wounds are of serious concern since broken cutaneous barriers can create an opening for potential COVID-19 infections. Innovation and Conclusion: As this virus continues to spread silently, mainly through asymptomatic carriers, an accurate and rapid identification of these cutaneous manifestations may be vital to early diagnosis and lead to possible better prognosis in COVID-19 patients. This systematic review and photo atlas provide a detailed analysis of the skin pathologies related to COVID-19. Study of these cutaneous manifestations and their pathogenesis, as well their significance in human health will help define COVID-19 in its entirety, which is a prerequisite to its effective management.

Section: Maculopapular/morbilliform Lesionsmentioning

confidence: 97%

Section: Urticarial Lesionsmentioning

confidence: 99%

Section: Urticarial Lesionsmentioning

confidence: 99%

See 1 more Smart Citation

Cutaneous Manifestations of COVID-19: A Systematic Review

Kaur

et al. 2021

Advances in Wound Care

133

189

“…Remdesivir (adenosine analog, RNA polymerase inhibitor) may cause rash, pruritus, or angioedema [19].…”

Section: Dermatological Adverse Reactions To Drugs Used In Treatment mentioning

confidence: 99%

“…Remdesiwir (analog adenozyny, inhibitor polimerazy RNA) może wywołać osutkę, świąd skóry lub obrzęk naczynioruchowy [19].…”

Section: Stosowanych U Pacjentów Z Covid-19unclassified

Dermatological manifestations of COVID-19: a practical summary of the current state of knowledge

Sławińska¹,

Nowicki²

2020

While COVID-19 initially appeared to be manifested primarily by respiratory symptoms, it is now known to be a multi-organ disease, also with dermatological manifestations. Cutaneous symptoms in patients with COVID-19 have a wide clinical spectrum. They may appear at any stage of the disease or as its sole manifestation. Further research is necessary to clarify the pathogenesis of these changes, their prognostic significance and therapeutic management. This article summarizes the current knowledge about changes occurring in the skin, mucous membranes and nails of patients diagnosed with COVID-19 and addresses the issue of drug-induced skin changes associated most common treatments of COVID-19. StReSzCzeNIe Mimo że początkowo wydawało się, że COVID-19 manifestuje się głównie objawami ze strony układu oddechowego, obecnie wiadomo, że jest to schorzenie wielonarządowe, a symptomy obejmują także skórę. Objawy skórne u pacjentów z COVID-19 wykazują szerokie spektrum kliniczne i mogą pojawić się na każdym etapie choroby, jak również być jedyną jej manifestacją. Niezbędne są dalsze badania, które pozwolą na wyjaśnienie patogenezy tych zmian, ich znaczenia prognostycznego oraz ustalenie postępowania terapeutycznego. W pracy podsumowano aktualny stan wiedzy na temat zmian w obrębie skóry, błon śluzowych oraz aparatu paznokciowego obserwowanych u pacjentów z rozpoznaniem choroby, a także wymieniono możliwe skórne działania niepożądane leków najczęściej stosowanych u tej grupy chorych.

Rook's Textbook of Dermatology

Viral Infections

Harwood,

Sterling

2024

Viruses can cause disease in the skin or mucosa by direct infection or, via a systemic infection, produce secondary skin abnormalities. The chapter reviews the viruses associated with skin lesions, outlining the pathophysiology, the clinical features, diagnostic methods and the approaches to treatment. Primary skin infection following direct contact occurs with poxviruses, some herpesviruses and papillomaviruses leading to visible features which may be readily diagnostic. Less specific skin changes are seen with systemic infections, when infection is often via mucosae or inoculation, for example with parvovirus, measles or coronavirus and for these infections, diagnosis will usually involve body fluid analysis.